Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 4/20 | 0.39 |
| ▸ | NOS1 | P29475 | 4/20 | 0.39 |
| ▸ | NOS2 | P35228 | 4/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10899848 | 0.89 | HRH4 (0.40) | HRH4HRH3NOS3NOS1NOS2 | |
| SCHEMBL10902493 | 0.84 | CHRM2 (0.37) | HRH4 | |
| SCHEMBL10902920 | 0.83 | DRD2 (0.40) | DRD2 | |
| SCHEMBL10899853 | 0.83 | KDM4E (0.39) | HRH4HRH3NOS3NOS1NOS2 | |
| SCHEMBL10901727 | 0.81 | FDFT1 (0.42) | NOS2DRD2 | |
| SCHEMBL10901822 | 0.80 | P2RY14 (0.41) | HRH4DRD2 | |
| SCHEMBL10901424 | 0.80 | QDPR (0.44) | HRH4HRH3DRD2LSS | |
| SCHEMBL10901738 | 0.79 | NPC1 (0.42) | HTR3A | |
| SCHEMBL10900558 | 0.79 | HTR2A (0.41) | DRD4DRD2 | |
| SCHEMBL10901737 | 0.79 | PLG (0.33) | DRD4LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4600719-A | Tetrahydropyridine and piperidine derivatives | CIBA GEIGY CORPORATION (US) | 1986-07-15 | — | — | US | claimed |
| EP-2629615-B1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | UNIV DUKE (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20160374957-A1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | UNIV DUKE (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468627-B2 | Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies | DUKE UNIVERSITY (US) | 2016-10-18 | — | — | US | disclosed |
| US-8703764-B2 | Combination therapy for dementia, depression and apathy | SHELDON LESLIE JAMES (CA) | 2014-04-22 | — | — | US | disclosed |
| US-20130338192-A1 | METHOD FOR AUGMENTING THE EFFECTS OF SEROTONIN REUPTAKE INHIBITORS | DUKE UNIVERSITY (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130230577-A1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | DUKE UNIVERSITY (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2629615-A1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | Duke University (US) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012054815-A1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | DUKE UNIVERSITY (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20090192166-A1 | METHOD FOR AUGMENTING THE EFFECTS OF SEROTONIN REUPTAKE INHIBITORS | DUKE UNIVERSITY (US) | 2009-07-30 | — | — | US | disclosed |
| EP-1713486-A4 | COMBINATION THERAPY FOR DEMENTIA,DEPRESSION AND APATHY | SHELDON LESLIE JAMES (CA) | 2009-04-29 | — | — | EP | disclosed |
| US-7517908-B2 | Method for augmenting the effects of serotonin reuptake inhibitors | DUKE UNIVERSITY (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1746985-A2 | METHOD FOR AUGMENTING THE EFFECTS OF SEROTONIN REUPTAKE INHIBITORS | DUKE UNIVERSITY (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060287299-A1 | Combination therapy for dementia, depression and apathy | SHELDON LESLIE J | 2006-12-21 | — | — | US | disclosed |
| EP-1713486-A1 | COMBINATION THERAPY FOR DEMENTIA,DEPRESSION AND APATHY | Sheldon, Leslie James (CA) | 2006-10-25 | — | — | EP | disclosed |
| US-20060142375-A1 | Method for augmenting the effects of serotonin reuptake inhibitors | DUKE UNIVERSITY | 2006-06-29 | — | — | US | disclosed |
| WO-2005112906-A2 | METHOD FOR AUGMENTING THE EFFECTS OF SEROTONIN REUPTAKE INHIBITORS | DUKE UNIVERSITY (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005053703-A1 | COMBINATION THERAPY FOR DEMENTIA, DEPRESSION AND APATHY | SHELDON LESLIE JAMES (CA) | 2005-06-16 | — | — | WO | disclosed |
| US-4600719-A | Tetrahydropyridine and piperidine derivatives | CIBA GEIGY CORPORATION (US) | 1986-07-15 | — | — | US | disclosed |
| US-4210655-A | Anti-depressant benzofuranyl piperidines | CIBA-GEIGY CORPORATION (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230577-A1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | TPH1, HTR5A, TPH2 | HRH4 470/4885HRH3 882/4885NOS3 1161/4885 |
| US-20160374957-A1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | TPH1, HTR5A, TPH2 | HRH4 460/4885HRH3 929/4885NOS3 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.